Acadia Pharmaceuticals Halts Further Clinical Trials for Pimavanserin After Disappointing Results


In a significant setback for Acadia Pharmaceuticals (ACAD.O), the California-based company announced on Monday its decision to cease further clinical trials of its antipsychotic drug, pimavanserin.

The decision follows the drug’s failure to demonstrate efficacy in improving negative symptoms of schizophrenia during a late-stage study. As a result of this announcement, shares of Acadia plummeted by 16% in extended trading, reflecting investor disappointment and concerns about the company’s future prospects.

Failure Of Pimavanserin Drug

Pimavanserin, marketed under the brand name Nuplazid, has faced challenges in securing regulatory approval for expanded indications in recent years. Previous attempts to gain approval for the treatment of psychosis related to dementia and Alzheimer’s disease in 2021 and 2022, respectively, were unsuccessful. The latest setback adds to the company’s struggles in diversifying the drug’s usage beyond its initial indication.

The decision not to proceed with further clinical trials was based on the results of a study involving 454 adult patients, where pimavanserin failed to outperform a placebo in reducing negative symptoms of schizophrenia. These symptoms, which include poor socialization and lack of motivation, are characteristic of the chronic mental disorder, which affects less than 1% of the U.S. population, according to the American Psychiatric Association.

Schizophrenia is known for causing distortions in thoughts, hallucinations, and feelings of fright and paranoia, presenting significant challenges for patients and caregivers alike. With the failure of pimavanserin to address these negative symptoms effectively, Acadia faces a setback in its efforts to provide innovative treatment options for individuals living with schizophrenia.

Despite this setback, Acadia had experienced success with Nuplazid in the past. In 2016, the drug became the first to receive approval in the United States for the treatment of hallucinations and delusions associated with psychosis in Parkinson’s disease. Nuplazid contributed substantially to Acadia’s revenue, generating $522.7 million in sales last year, comprising nearly 72% of the company’s total revenue.

However, the reliance on Nuplazid for a significant portion of its revenue highlights Acadia’s vulnerability to setbacks and challenges in diversifying its product portfolio. With the failure of pimavanserin to expand its indications, the company faces increased pressure to identify new avenues for growth and innovation in the competitive pharmaceutical landscape.

In contrast to Nuplazid, which targets a specific subset of patients with Parkinson’s disease psychosis, treatments approved for schizophrenia in the U.S. encompass a broader range of antipsychotic generic drugs, including risperidone and olanzapine. These established medications have demonstrated efficacy in managing symptoms associated with schizophrenia, posing stiff competition for novel therapies like pimavanserin.

Moving forward, Acadia Pharmaceuticals must reassess its research and development strategies, focusing on identifying potential breakthroughs in the treatment of neurological and psychiatric disorders. While the setback with pimavanserin is undoubtedly disappointing, it underscores the inherent challenges and uncertainties inherent in drug development and highlights the importance of continued innovation and perseverance in the pursuit of improved patient outcomes.

In conclusion, Acadia Pharmaceuticals’ decision to halt further clinical trials of pimavanserin marks a significant setback in its efforts to expand the drug’s indications beyond its initial approval. With shares tumbling and concerns about the company’s future, Acadia faces renewed challenges in diversifying its product portfolio and maintaining its competitive edge in the pharmaceutical industry.

— Share —

— About the Author —

Leave a Reply

Up Next

Beyond Chemical Imbalances: Researchers Shed Light on Social Root Causes Of Depression

In a recent letter to the editor published in Molecular Psychiatry, researchers led by Joanna Moncrieff present a compelling argument challenging the conventional understanding of depression. They assert that rather than being solely attributed to chemical imbalances in the brain, and discuss the social root causes of depression.

According to Moncrieff et al., the evidence for brain differences in depression is lacking, while there is substantial support for the influence of social and environmental factors on mental health.

They argue that the circumstances of life, such as stress and adversity, play a more significant role in shaping depressive symptoms than neuro

Up Next

Study Reveals Presence of Microplastics in Human Brain: Concerns Rise Over Health Implications

In a groundbreaking revelation, researchers from the University of New Mexico have discovered microplastics infiltrating human brain tissue, as reported in a study published in the journal Environment Health Perspectives. The study sheds light on the pervasive presence of microplastics in various organs of the body, including the kidneys, liver, and brain.

Eliseo Castillo, an associate professor leading the research, underscores the widespread distribution of microplastics in the environment, emphasizing their presence in water sources, food items, and even the air we breathe.

Previous studies have estimated that individuals ingest approximately five grams of microplastics weekly, equivalent to the weight of a credit card.

Up Next

Study Reveals Significant Genetic Link Between Treatment-Resistant Depression and Family History

In a groundbreaking study published in the journal JAMA Psychiatry, researchers have uncovered a substantial genetic link between treatment-resistant depression (TRD) and family history.

Led by Dr. Cheng-Ta Li, a professor of medicine at the National Yang-Ming Chiao Tung University in Taipei, Taiwan, the study utilized extensive national health insurance data to investigate the transmission of TRD across generations and its association with other psychiatric disorders.

The findings of the study are particularly significant, as they shed light on the hereditary nature of TRD and its implications for early intervention and treatment.

Up Next

FDA Clears Prescription Digital Therapeutic for Adults with Major Depressive Disorder

The FDA has recently cleared a groundbreaking prescription digital therapeutic, known as Rejoyn, for the treatment of major depressive disorder (MDD) symptoms in adults. This innovative therapy, developed by Otsuka Pharmaceutical Co. Ltd. in collaboration with Click Therapeutics Inc., aims to provide adjunctive care for individuals who have been prescribed antidepressants as part of clinician-managed outpatient treatment.

Rejoyn is a 6-week treatment program designed to assist individuals aged 22 years and older in regulating their emotions through a combination of clinically validated cognitive training exercises and therapeutic lessons.

The therapy utilizes digital platforms to deliver pe

Up Next

Sweet Science: How Chocolate’s Theobromine May Aid Weight Loss and Alzheimer’s Prevention

A recent study conducted by researchers at Zhengzhou University in China suggests that indulging in chocolate could offer various health benefits, including weight loss assistance and Alzheimer’s prevention.

Published in the Journal of Functional Foods, the study highlights the potential of a chemical compound found in chocolate called theobromine to positively impact both the body and the brain.

Theobromine, present in cocoa beans, boasts anti-inflammatory properties and is rich in antioxidants, making it beneficial for brain health. According to scientists, this compound can protect against Alzhei

Up Next

New Study Finds High Genetic Risk for Obesity May Require Over 14,500 Daily Steps

A recent study published in JAMA Network Open reveals a significant association between genetic risk for obesity and the amount of physical activity required to mitigate the risk.

Led by Dr. Evan Brittain, associate professor of medicine at Vanderbilt University Medical Center, the study analyzed data from 3,124 participants in the National Institutes of Health’s All of Us Research Program to explore the link between genetic predisposition to obesity and recommended step counts for reducing the genetic risk of developing the condition.

Findings from the study indicate that individuals with a higher genetic risk of obesity may need to undertake more physical activity

Up Next

Ketogenic Diets Show Promise for Bipolar Disorder and Schizophrenia Treatment, Stanford Study Finds

A recent study led by researchers at Stanford University suggests that ketogenic diets may offer benefits for individuals with bipolar disorder and schizophrenia, shedding light on the potential role of diet in managing serious mental illnesses.

The findings, published in Psychiatry Research, highlight the positive impact of a ketogenic regime on both psychiatric outcomes and metabolic syndromes commonly associated with these conditions.

Unlike traditional diets, ketogenic diets are characterized by high fat, moderate protein, and very low carbohydrate intake. The study, led by Dr. Shebani Sethi, a clinical ass